iBio Inc (IBIO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 605.66 is considered Overvalued compared with the five-year average of -3.90. The fair price of iBio Inc (IBIO) is between 0.16 to 1.41 according to relative valuation method. Compared to the current price of 2.69 USD , iBio Inc By Overvalued By 91.12%.

Relative Value

Fair Zone

0.16-1.41

Current Price：2.69

91.12%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is iBio Inc (IBIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

iBio Inc (IBIO) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.89, the current P/B ratio is approximately -17.78% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about -35.58% higher. iBio Inc (IBIO) has a Forward Free Cash Flow (FCF) yield of approximately -38.09%. Compared to its 3-year average FCF yield of -233.35%, the current FCF yield is approximately -83.68% lower. Relative to its 5-year average FCF yield of -192.19%, the current FCF yield is about -80.18% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IBIO competitors is 101.79, providing a benchmark for relative valuation. iBio Inc Corp (IBIO.A) exhibits a P/S ratio of 605.66, which is 495.04% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IBIO currently overvalued or undervalued?

What is iBio Inc (IBIO) fair value?

IBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of iBio Inc (IBIO) is between 0.16 to 1.41 according to relative valuation method.

How does IBIO's valuation metrics compare to the industry average?

The average P/S ratio for IBIO's competitors is 101.79, providing a benchmark for relative valuation. iBio Inc Corp (IBIO) exhibits a P/S ratio of 605.66, which is 495.04% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for iBio Inc (IBIO) as of Mar 03 2026?

As of Mar 03 2026, iBio Inc (IBIO) has a P/B ratio of 0.73. This indicates that the market values IBIO at 0.73 times its book value.

What is the current FCF Yield for iBio Inc (IBIO) as of Mar 03 2026?

As of Mar 03 2026, iBio Inc (IBIO) has a FCF Yield of -38.09%. This means that for every dollar of iBio Inc's market capitalization, the company generates -38.09 cents in free cash flow.

What is the current Forward P/E ratio for iBio Inc (IBIO) as of Mar 03 2026?

As of Mar 03 2026, iBio Inc (IBIO) has a Forward P/E ratio of -6.38. This means the market is willing to pay $-6.38 for every dollar of iBio Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for iBio Inc (IBIO) as of Mar 03 2026?

As of Mar 03 2026, iBio Inc (IBIO) has a Forward P/S ratio of 605.66. This means the market is valuing IBIO at $605.66 for every dollar of expected revenue over the next 12 months.

IBIO Valuation